TABLE 2.
Symbol | Chr:Start-End | Gene ID | H3K272/3 peak(s) in KL-treated cells | Promotor overlap (%) |
---|---|---|---|---|
Wnt4 | chr4:137277489–137299726 | ENSMUSG00000036856 | chr4:137274634–137274877; chr4:137276224–137277069 | 33 |
Wnt9a | chr11:59306928–59333552 | ENSMUSG00000000126 | chr11:59304349–59305664 | 40 |
Wnt10a | chr1:74791516–74804179 | ENSMUSG00000026167 | chr1:74789946–74790493 | 17 |
Fzd3 | chr14:65201026–65262463 | ENSMUSG00000007989 | chr14:65261701–65263591 | 43 |
Fzd9 | chr5:135248938–135251230 | ENSMUSG00000049551 | chr5:135252831–135253153 | 10 |
Frzb | chr2:80411970–80447625 | ENSMUSG00000027004 | chr2:80446165–80447428 | 3 |
Wisp3 | chr10:39150971–39163794 | ENSMUSG00000062074 | chr10:39164763–39165022; chr10:39166089–39167811 | 29 |
Csnk2a2 | chr8:95446096–95488820 | ENSMUSG00000046707 | chr8:95491364–95492299 | 14 |
Pp2cb | chr8:33599621–33619794 | ENSMUSG00000009630 | chr8:33597564–33598858 | 39 |
Sfrp2 | chr3:83766321–83774316 | ENSMUSG00000027996 | chr3:83766030–83766774 | 18 |
Csnk1e | chr15:79417856–79443919 | ENSMUSG00000022433 | chr15:79444679–79446189 | 46 |
Nkd2 | chr13:73818534–73847631 | ENSMUSG00000021567 | chr13:73848780–73850045 | 38 |
Nkd1 | chr8:88521344–88594887 | ENSMUSG00000031661 | chr8:88520969–88524273 | 20 |
Shisa2 | chr14:59625281–59631658 | ENSMUSG00000044461 | chr14:59625308–59626307 | 8 |
Note: Promoter overlap percentage indicates the percent of a given promoter overlapping with H3K27me2/3 peak(s) in the Klotho-treated condition. Notably, all listed promoters have 0% overlap with H3K27me2/3 peaks in the vehicle-treated control condition, which suggests that these Wnt-related promoters have preferential heterochromatic mark deposition under Klotho stimulation. Column names indicate: gene symbol, gene location (chr:start-end), Ensemble gene ID, location of broad peaks, and promotor overlap (%) with H3K27me2/3 peaks in C2C12 cells treated with recombinant Klotho for 48 h.